A Market That Now Rewards Discipline
Healthcare investing is moving into a new chapter. The old playbook of rapid expansion, heavy spending and growth at any cost is being replaced by a more disciplined approach. At the Global Investment Leaders Club gathering, investors, family offices, healthcare executives and founders discussed how the market is changing, what founders must now prove and how investors are identifying companies that can scale without burning capital endlessly.
The central message was clear: healthcare innovation is still highly attractive, but only when it is supported by strong economics, commercial clarity and a real path to long term value.
Ross Morton, Managing Partner at Nodenza, captured the moment when he said, “the old models are quickly becoming broken.” For him, the opportunity remains strong, especially in novel technologies, deep tech and cross border product launches. However, the companies that win will be the ones that understand where value is being created and how to reach markets where that value can be fully recognized.
The Pressure Inside Healthcare Systems
A US-based investor pointed directly to the structural pressure in the US healthcare system. He described it as “an unsustainable system,” shaped by an aging population and an opaque third party payer model. In his view, the next phase of healthcare “will require efficiency and cost savings” and should move more toward “prevention rather than treatment of symptoms.”
This creates a major opening for founders, but also a higher standard. Startups cannot rely only on scientific strength or market size. They need to show how their solution fits into a healthcare environment where payers, providers and patients are all under cost pressure.
The Patient Becomes the Market Driver
Nola Masterson, Venture Partner at Portfolia.co, highlighted another force reshaping healthcare: the patient. She said that “the CEO has become the patient,” because patients are increasingly searching for what works for them, often outside traditional channels. This patient driven shift creates demand for solutions in women’s health, digital care, wellness, AI supported healthcare and tools that improve outcomes in practical ways.
At the same time, she warned that the startup environment remains difficult. “There are no exits,” she said, explaining that IPO markets are largely closed for healthcare companies and that M&A has become the main route for investor liquidity. For founders, that means building a company that can attract buyers, partners or revenue, not just attention.
From Growth Stories to Margin Logic
Nirmal Patel, Director at Hawk Family Office, the investment market is evolving beyond a singular focus on growth. Outside the most crowded AI segments, investors and founders are placing greater emphasis on sustainable margins and operational efficiency. AI is helping companies accomplish more with smaller teams and lower capital requirements, creating a pathway to stronger unit economics, earlier margin resilience and continuing revenue growth.
Ambuj Mathur, Managing Partner at Indite Ventures LLP, brought the conversation back to investor logic. “As an investor we ultimately have to figure out where we make money,” he said. His view was that healthcare investing should not be based only on the hope of exiting at a higher valuation. Instead, investors should help companies reach a logical commercial outcome.
He also pointed to the potential of AI in drug development, especially if it can “shave off 8 to 10 months of drug development time.” The value is not only in saved cost, but in the multiplier effect of reaching approvals and markets sooner.
Commercial Plans Under the Microscope
Another investor has explained that the healthcare market now has far more molecules, platforms and innovation than before. Because of that, investors and strategic partners are becoming more selective. “We really pressure test the commercial plan,” he said.
His advice to entrepreneurs was highly practical. Founders must explain who the users are, how the product will sell, what the go to market strategy looks like and how reimbursement will work. In today’s market, commercial readiness is no longer something to solve later. It is part of the investment case from the beginning.
CEOs Who Can Do the Math
A partner of a venture capital firm, focused on leadership and execution. “I’m only investing in CEOs who can do math,” he said. For him, financial discipline is not optional. Founders must understand budgeting, when to trim, when to accelerate and how each decision affects the company’s survival.
He also argued that startups need someone focused on AI operations, not simply to use AI as a buzzword, but to identify tools that can speed development, improve market fit and make the company more efficient.
Growth With Control
Nicholas Watkins, Co-founder and Managing Partner at White Cloud Capital, summarized the balance that founders must strike. “We can’t just keep pouring in money on the promises of jam tomorrow, but equally you can’t starve the company of resources either,” he said. His point reflects the heart of healthcare’s shift of focus on having a credible route to achieving a profit margin. Capital still matters and requires the prospect of a return."
The great recalibration of healthcare is not the end of ambition. It is the start of a more mature investment cycle. The companies most likely to succeed will be those that combine strong science, patient relevance, reimbursement clarity, commercial discipline and credible margins.
Growth still matters. But in this new healthcare market, growth must now prove that it can pay for itself.
